Johnson & Johnson has filled in some of the details of its $55 billion investment in US facilities announced earlier this ...

After UK Health Secretary Wes Streeting sent a letter to the pharma industry, warning that he will withdraw from negotiations ...

The positive data from the Phase 3 Denali trial showed that NCX 470, a nitric oxide-donating bimatoprost eyedrop formulation, ...

This month’s executive moves in the agency, consultancy, and investor sectors reflect a growing emphasis on strategic ...

Iterum Therapeutics has become the first drugmaker to bring an oral antibiotic in the penem class to market in the US, ...

Twin Health has raised another $53 million to fund its 'digital twin' platform, which provides a model of a patient's unique ...

Ionis has won an FDA green light for an RNA-based hereditary angioedema (HAE) treatment, Dawnzera, that can be ...

Among the plans will be greater first-line use of SGLT-2 inhibitors or 'gliflozin' drugs, which are mainly used second-line ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Suzanne Aitken, SVP of managed access at Clinigen, ...

When it comes to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro there’s a lot to talk about, from the science behind the ...

And while pharma marketing agencies are embracing AI like everyone else, most are using AI tools on a case-by-case basis to ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...